Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay

Apixaban and other factor Xa (FXa) inhibitors are in late-stage clinical development for prevention and treatment of thromboembolic diseases. Although routine monitoring will not be required, in certain situations assessment of drug level may be helpful. This study evaluated the suitability of comme...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Thrombosis and haemostasis Ročník 104; číslo 6; s. 1263
Hlavní autoři:	Barrett, Yu Chen, Wang, Zhaoqing, Frost, Charles, Shenker, Andrew
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Germany 01.12.2010
Témata:	Anticoagulants - blood Anticoagulants - therapeutic use Blood Coagulation - drug effects Blood Coagulation Tests Clinical Trials, Phase II as Topic Dose-Response Relationship, Drug Drug Monitoring - methods Factor Xa Inhibitors Humans International Normalized Ratio Isoxazoles - blood Morpholines - blood Predictive Value of Tests Prothrombin Time Pyrazoles - blood Pyrazoles - therapeutic use Pyridones - blood Pyridones - therapeutic use Reproducibility of Results Rivaroxaban Thiophenes - blood Venous Thromboembolism - blood Venous Thromboembolism - drug therapy
ISSN:	0340-6245, 2567-689X, 2567-689X
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!